自体肿瘤抗原致敏DC-CIK联合化疗治疗晚期肺腺癌的疗效  

Clinical effectiveness of autologous tumor antigen-pulsed dendritic cell-cytokine induced killer cells combined with chemotherapy in treatment of advanced lung adenocarcinoma

作　　者：杨佳[1] 顾国民[1] 王秀丽[1] 李晓琴[1] 展翼翼 刘春玲[1] 

机构地区：[1]新疆医科大学附属肿瘤医院肺内科二病区,新疆乌鲁木齐830011

出　　处：《中国肿瘤生物治疗杂志》2016年第1期83-88,共6页Chinese Journal of Cancer Biotherapy

基　　金：吴阶平医学基金会资助项目(No.320675012239);新疆医科大学科研创新基金资助项目(No.XYDCX201485)~~

摘　　要：目的:探讨自体肿瘤抗原致敏树突状细胞-细胞因子诱导的杀伤细胞(dendritic cell-cytokine induced killer cell,DC-CIK)联合化疗治疗晚期肺腺癌的临床疗效和安全性。方法:选取2013年1月至2013年12月在新疆医科大学附属肿瘤医院治疗的120例晚期肺腺癌患者,60例行自体肿瘤抗原致敏DC-CIK联合化疗(联合组),60例行单纯化疗(化疗组),评价两组患者治疗后免疫功能、毒副反应、临床疗效、生活质量、无进展生存期和总生存期。结果:联合组治疗前后外周血T细胞亚群无明显变化(P>0.05),而化疗组治疗后外周血中CD3^+、CD3^+CD4^+、CD3^+CD8^+、CD3^-CD56^+细胞百分比明显低于治疗前,且较联合组显著下降(P<0.05);联合组较化疗组的恶心呕吐、Ⅲ-Ⅳ度骨髓抑制发生率均降低,差异有统计学意义(P<0.05);联合治疗组患者治疗后体力、食欲、睡眠较单纯化疗组改善明显(P<0.05)。联合组和化疗组患者的无进展生存期比较差异无统计学意义(6个月vs 4.5个月,P>0.05),联合组患者的总生存期较化疗组患者长(16个月vs 11.5个月,P<0.05)。结论:自体肿瘤抗原致敏DC-CIK联合化疗较单纯化疗治疗晚期肺腺癌,可明显改善患者由于化疗毒性导致的免疫功能降低,提高患者生活质量,延长总生存,减轻不良反应,提高总体疗效。Objective：To investigate the clinical efficacy and safety of autologous tumor antigen-pulsed DC-CIK （den- dritic cell-cytokine induced killer cell ） combined with chemotherapy in treatment of advanced lung adenocarcinoma. Methods： 120 patients with advanced lung adenocarcinoma treated in the Affiliated Tumor Hospital of Xinjiang Medical University from Jan 2013 to December 2013 were selected in this study; 60 patients were treated with autologous tumor an- tigen-pulsed DC-CIK combined with chemotherapy （combination group） , the other 60 patients were treated with chemo- therapy only （chemotherapy group） ; the immune function, curative effect, adverse reactions, quality of life （QOL）, pro- gression free survival （PFS） and overall survival （OS） after treatment were separately evaluated in the two groups . Re- sults： Compared to the values of pre-treatment, there was no significant difference in peripheral blood T cell subsets in combination group （P 〉 0.05 ） ; Compared to pre-treatment value, the post-treatment percentage of CD3^＋ , CD3^＋ CD4^＋ , CD3^＋ CD8^＋ and CD3^- CD56^＋ in peripheral blood decreased significantly in chemotherapy group, and it was significant lower than that of combination group （P 〈 0.05 ） ; the incidences of nausea and vomiting,Ⅲ-Ⅳ degree myelosuppression in combination group were less than that of chemotherapy group, and the difference was statistically significant （P 〈0. 05） ; after treatment, compared with chemotherapy group, the combination of sleep, appetite and physical strength in combination group was significantly improved （P 〈 0.05 ）. There was no significant difference in PFS between combina- tion group and chemotherapy group （6 months vs 4.5 months, P 〉 0.05 ）, however, the OS of combination group was lon- ger than that of chemotherapy group （ 16 months vs 11.5 months, P 〈 0.05 ）. Conclusion： Autologous tumor antigen- pulsed DC-CIK combination with chemotherapy, compared with chemotherapy alone, ca

关 键 词：肺腺癌 自身抗原 树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK) 过继细胞免疫治疗 化疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.54[医药卫生—临床医学]